Faculty Appointments
Patient Care Setting
Allergy, Immunology & Rheumatology
Biography
Dr. Anolik is an adult rheumatologist who practices in the University of Rochester's Lupus Clinic. Her research interests include the role of B cells in the pathophysiology of human systemic lupus, the study of new immuno-modulatory treatments for lupus, and B cell regulation of bone homeostasis in rheumatoid arthritis. As part of the research group at the University of Rochester she has been one of the pioneers in the use of B-cell depletion for the therapy of autoimmune diseases and investigation of the effects of B cell depletion on immune function in SLE patients. She has also pioneered the use of tonsil and bone marrow biopsy as a means of probing immune dysregulation in autoimmune diseases, including SLE and RA.
Research
Dr. Anolik's research interests include the role of B cells in the pathophysiology of human systemic lupus, the study of new immuno-modulatory treatments for lupus and rheumatoid arthritis, and autoantibody independent functions for B cells including interaction with T cells, the innate immune compartment, and bone cells. As part of the research group at the University of Rochester she has been one of the pioneers in the use of B-cell depletion for the therapy of autoimmune diseases and investigation of the effects of B cell depletion on immune function in SLE patients. She has also pioneered the use of tonsil and bone marrow biopsy as a means of probing immune dysregulation in autoimmune diseases, including SLE and RA.
Credentials
Specialties
- Internal Medicine
- Rheumatology - American Board of Internal Medicine
Education
1994
Ph.D | Univ. of Rochester School of Medicine and Dentistry
Biochemistry
1996
MD | Univ. of Rochester School of Medicine and Dentistry
Post-doctoral Training & Residency
07/01/1999 - 06/30/2001
Fellowship in Rheumatology at University of Rochester Medical Center
07/01/1997 - 06/30/1999
Residency in Internal Medicine at University of Rochester Medical Center
07/01/1996 - 06/30/1997
Internship in Internal Medicine at University of Rochester Medical Center
VIEW ALL expand_more
Awards
2015
American Society for Clinical Investigation
2008
Eisenberg Memorial Lupus Lectureship
Sponsor: University of MO-Columbia
Location: Columbia, MO
2006 - 2008
Lawrence Kohn Senior Teaching Fellow
2005
Edmund Dubois Memorial Lectureship Award
Sponsor: American College of Rheumatology
2003
Buswell Fellowship
Sponsor: University of Rochester Dept of Medicine
Location: Rochester, NY
2001
Rheumatology Fellow Award
Sponsor: American College of Rheumatology
2000 - 2002
NIH Training Grant T32-AI07169-16
Sponsor: University of Rochester
Location: Rochester, NY
1999 - 2000
Stuber Fellowship
Sponsor: University of Rochester
Location: Rochester, NY
1999
Raphael Dolin Resident Research Award
Sponsor: University of Rochester
Location: Rochester, NY
1994 - 1996
Medical Scientist Training Program Scholarship
Sponsor: NIH
Location: University of Rochester
1991 - 1992
Stotz Fellowship
Sponsor: University of Rochester Biochemistry Dept
Location: Rochester, NY
1988 - 1990
Medical Scientist Training Program Scholarship
Sponsor: NIH
Location: University of Rochester
1988 - 1989
Dean's Letter of Recognition
Sponsor: University of Rochester
Location: Rochester, NY
1988
Sigma Xi Scientific Research Society
Location: Swathmore College
1988
Outstanding Senior Chemistry Student Award
Sponsor: American Institute of Chemists
Location: Swathmore College
1988
Phi Beta Kappa
Location: Swathmore College
1987
Summer Research Fellowship
Sponsor: Dana Foundation
Location: Swathmore College
VIEW ALL expand_more
Clinical Trials
A Double-Blind, Placebo-Controlled Randomized, Multicenter Study to Assess Changes in Omega-3 Index in Erythrocytes and Health Benefit After 24 Weeks of Daily Consumption of AKBM-3031 (Omega-3 Phospholipids From Krill), Followed by a 24 Week Open-Label Extension, in Patients With Systemic Lupus Erythematosus (SLE)
Lead Researcher: Jennifer Howitt Anolik MD, PhD
A randomized, double-blind controlled, multicenter study in SLE patients given AKBM-3031 or
placebo for 24 weeks (randomized period) and followed by an open label extension (OLE)
treatment with AKBM-3031 for the next 24 weeks. Patients will be maintained on stable doses
of background medications, except for glucocorticoids. Decreases in doses of glucocorticoids
will be encouraged during the first 20 weeks of both the randomized and open label extension
portions of the trial. Stable doses of glucocorticoids and other background medications are
required during weeks 20-22 and 44-48. If indicated by the PI, brief increases in
corticosteroids are permitted during the first 20 weeks of both the blinded and open label
extension portion of the trial. The increase in prednisone (or equivalent) dose is limited to
2X the back-ground level to a maximum of 20 mg/day for a maximum of 1 week (7 days) or to a
single administration of intravenous methylprednisolone or equivalent at a maximum dose of
500mg. Stable doses of glucocorticoids and other background medications are required during
weeks 20-22 and 44-48
View Study Details
Med/AIR Subject Database and Tissue Repository
Lead Researcher: Jennifer Howitt Anolik MD, PhD
Autoimmune diseases affect the immune system and are typically chronic conditions in which the immune system has an overactive response against substances and tissues that are normally present in the body. How autoimmunity develops, progresses, induces immunological abnormalities and leads to disease remains largely unknown, producing the need for further research. However, because the necessary samples are unique and somewhat rare, the ability to do research can at times be hindered.
One purpose of this protocol is to establish a database that will serve as both a contact and research database. Subjects who are currently participating in one of our studies as well as those who are interested in participating in future research at the University of Rochester will be consented so that we may store their personal information in a division database. We will also store data collected during the conduct of IRB approved studies which reference this protocol.
Healthy controls and individuals with diseases affecting the immune system may be consented and enrolled into this protocol.
View Study Details
Publications
Journal Articles
4/22/2020
Wei K, Korsunsky I, Marshall JL, Gao A, Watts GFM, Major T, Croft AP, Watts J, Blazar PE, Lange JK, Thornhill TS, Filer A, Raza K, Donlin LT, Siebel CW, Buckley CD, Raychaudhuri S, Brenner MB. "Notch signalling drives synovial fibroblast identity and arthritis pathology." Nature.. 2020 Apr 22; Epub 2020 Apr 22.
1/14/2020
Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, Tomar D, Woodruff MC, Simon Z, Bugrovsky R, Blalock EL, Scharer CD, Tipton CM, Wei C, Lim SS, Petri M, Niewold TB, Anolik JH, Gibson G, Eun-Hyung Lee F, Boss JM, Lund FE, Sanz I. "Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus." Immunity.. 2020 Jan 14; 52(1):203.
12/2019
Barnas JL, Looney RJ, Anolik JH. "B cell targeted therapies in autoimmune disease." Current opinion in immunology.. 2019 Dec 0; 61:92-99. Epub 2019 Nov 14.
VIEW ALL PUBLICATIONS
Videos
play_circle_filled
First New Lupus Drug in 50 Years: What Promise Might it Hold?
play_circle_filled
Pop Star Brings Disease to Spotlight